GEN Exclusives

More »

Tutorials

More »

For full access to this article login to GEN Select now.

May 1, 2014 (Vol. 34, No. 9)

Closed Processing for Cell Therapies

Engineering Risk Reduction and Patient Safety during Manufacturing

  • Production of patient-specific cell-based therapies (PSCT) presents unique scale and cost challenges not seen in pharmaceuticals and biologics manufacturing. Rather than scaling up to ...

Not registered yet? Please fill out the form below and enjoy complimentary access to this and an exclusive collection of premium content and personalization features as a GEN Select insider. Learn More.

    • Do not put any letters or characters here if you are not a spy program.
    •  

Get GEN Select Access Now



Jobs

GEN Jobs powered by HireLifeScience.com connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
 Searching...
More »

GEN Poll

More » Poll Results »

New Drugs for Ebola

Do you think that biopharma companies should not have to go through the normal drug approval process in order to get potential life-saving therapies to Ebola patients more quickly?